“塞来昔布”、“氟西汀”、“酮康唑”、“舍曲林”、“噻氯匹定”-"celecoxib","fluoxetine","ketoconazole","sertraline","ticlopidine"
变量_单倍型
CYP2C19*1, CYP2C19*16
药物名称(英)
"celecoxib","fluoxetine","ketoconazole","sertraline","ticlopidine"
药物名称(中)
“塞来昔布”、“氟西汀”、“酮康唑”、“舍曲林”、“噻氯匹定”
记事
The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. "Sensitivity" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine.
专家论述
CYP2C19 *16 is associated with decreased sensitivity to celecoxib, fluoxetine, ketoconazole, sertraline and ticlopidine as compared to CYP2C19 *1.